Showing 61-70 of 856 results for "".
Leading Dermatologists Summarize Maui Derm Presentations
https://practicaldermatology.com/videos/dermwire-tv/leading-dermatologists-summarize-maui-derm-presentations/32839/In this week's DermwireTV, top thought leaders provide a summary of their presentations at Maui Derm; a new analysis examines a link between hidradenitis suppurativa genetics and coronary artery disease risk; and the president of Castle Biosciences joins us for this week's C-Suite Chats fJoin the (Buying) Club
https://practicaldermatology.com/topics/practice-management/join-the-buying-club/18547/Every practice must buy a certain amount of supplies month to month. There's no getting around it. But you can save on those purchases. Among your options, consider a buying club. Jay A. Shorr, BA, MBM-C, CAC I-IX explains.Is this the Golden Age of Hair Loss Treatment?
https://practicaldermatology.com/topics/hair-nails/is-this-the-golden-age-of-hair-loss-treatment/24036/A perfect storm of many new, unrelated scientific developments also has the potential to fundamentally reshape the way we think about a disease or disease group. Dr. Peter C. Friedman believes many recent breakthroughs have profoundly changed how general dermatologists can manage patients with hairISDPA: Dr. Lio on Alternative and Innovative Approaches
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-lio-alternative-and-innovative-approaches/27066/Practical Dermatology Editorial Board member Peter Lio, MD, discusses the presentation that he and Tracee Blackburn, PA-C, gave about alternative and innovative approaches in dermatology, as well as the importance of educational engagement between physician assistants and dermatologists, at the IlliBiologics Preferred after MACE in PsO, Plus More
https://practicaldermatology.com/series/dermwire-tv/biologics-preferred-after-mace-in-pso-plus-more/37882/In this edition of DermwireTV, new research shows biologic use use after MACE is persistent, signaling strong patient preference; a new study shows that early stress may raise lifelong psoriasis risk; and a new C-Suite Chat highlights a new antibody showing promise in treating atopic dermatitisAAD Leaders Discuss New Goals and Initiatives
https://practicaldermatology.com/series/dermwire-tv/aad-leaders-discuss-new-goals-and-initiatives/33154/In this week's DermwireTV, leaders of the American Academy of Dermatology (AAD) discuss the key issues facing the specialty; a new study examines nicotinamide exposure and the risk of major adverse cardiovascular events; and in our C-Suite Chats segment, we hear from an Executive Director at TakeNemluvio Gains Two Major Indications in Europe
https://practicaldermatology.com/videos/dermwire-tv/nemluvio-gains-two-major-indications-in-europe/32982/In this week's DermwireTV, Nemluvio is approved for two new indications in Europe; new patient-centric guidelines for generalized pustular psoriasis (GPP) management are unveiled; and in our C-Suite Chats feature, we are joined by the Co-Founder and CEO of Veradermics.Initiating Biologics
https://practicaldermatology.com/topics/psoriasis/initiating-biologics/19986/Kara S. Gooding, MMS, PA-C offers an overview of a panel discussion about initiating treatment with biologics. The panel shared real-world applications, plus tips on lab monitoring, managing side effects, and choosing the right biologic.The Importance of Planning
https://practicaldermatology.com/topics/practice-management/the-importance-of-planning/19082/Failing to plan is planning to fail, say Jay A. Shorr, BA, MBM-C, CAC I-V and Mara Shorr, BS, CAC II-V of The Best Medical Business Solutions. They tell aesthetic practices how to lay the foundation for success in minimally invasive procedures.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/videos/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.